Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107.

Twardowski, Przemyslaw W; Tangen, Catherine M; Wu, Xiwei; Plets, Melissa R; Plimack, Elizabeth R; Agarwal, Neeraj; Vogelzang, Nicholas J; Wang, Jinhui; Tao, Shu; Thompson, Ian M; Lara, Primo

Twardowski, Przemyslaw W; Tangen, Catherine M; Wu, Xiwei; Plets, Melissa R; Plimack, Elizabeth R; Agarwal, Neeraj; Vogelzang, Nicholas J; Wang, Jinhui; Tao, Shu; Thompson, Ian M; Lara, Primo.

Afiliação

Twardowski PW; City of Hope, Duarte, CA, USA.
Tangen CM; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Wu X; City of Hope, Duarte, CA, USA.
Plets MR; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Plimack ER; Fox Chase Cancer Center, Philadelphia, PA, USA.
Agarwal N; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA.
Vogelzang NJ; Carolina Urologic Research Center, The US Oncology Network, Myrtle Beach, SC, USA.
Wang J; City of Hope, Duarte, CA, USA.
Tao S; City of Hope, Duarte, CA, USA.
Thompson IM; CHRISTUS Santa Rosa Medical Center Hospital, Texas Urology Group, San Antonio, TX, USA.
Lara P; UC Davis Comprehensive Cancer Center, Sacramento, CA, USA.